North China Pharmaceutical Company.Ltd (SHA:600812)
6.09
+0.01 (0.16%)
May 21, 2025, 2:45 PM CST
SHA:600812 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 166.33 | 126.99 | 4.89 | -689.23 | 18.73 | 97.32 | Upgrade
|
Depreciation & Amortization | 858.93 | 858.93 | 878.05 | 779.02 | 703.23 | 620.12 | Upgrade
|
Other Amortization | 16.48 | 16.48 | 10.79 | 10.41 | 8.68 | 23.06 | Upgrade
|
Loss (Gain) From Sale of Assets | -0.44 | -0.44 | -0.76 | -0.44 | -3.4 | -1.07 | Upgrade
|
Asset Writedown & Restructuring Costs | 4.73 | 4.73 | 0.05 | 0.24 | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | -46.16 | -46.16 | -46.85 | -44.02 | -39.12 | -26.44 | Upgrade
|
Provision & Write-off of Bad Debts | 41.5 | 41.5 | 10.56 | 44.94 | 22.77 | 37.37 | Upgrade
|
Other Operating Activities | 96.52 | 539.63 | 550.93 | 1,404 | 641.66 | 595.52 | Upgrade
|
Change in Accounts Receivable | 377.13 | 377.13 | 342.83 | -578.35 | -329.25 | -137.84 | Upgrade
|
Change in Inventory | 94.32 | 94.32 | -87.11 | -191.92 | 86.61 | -247.68 | Upgrade
|
Change in Accounts Payable | -792.32 | -792.32 | -637.27 | 275.22 | -58.2 | -207.65 | Upgrade
|
Operating Cash Flow | 825.8 | 1,230 | 1,024 | 1,004 | 1,050 | 752.15 | Upgrade
|
Operating Cash Flow Growth | -41.16% | 20.04% | 1.98% | -4.37% | 39.63% | -1.51% | Upgrade
|
Capital Expenditures | -712.12 | -784.22 | -623.04 | -549.58 | -547.5 | -1,007 | Upgrade
|
Sale of Property, Plant & Equipment | 1.28 | 1.27 | 0.69 | 22.26 | 6.54 | 141.81 | Upgrade
|
Investment in Securities | -674.5 | -674.5 | -260 | -2 | -240 | 2.49 | Upgrade
|
Other Investing Activities | 570.72 | 510.72 | 0.59 | 0.86 | 1.69 | 18.94 | Upgrade
|
Investing Cash Flow | -814.63 | -946.73 | -881.75 | -528.46 | -779.26 | -843.58 | Upgrade
|
Short-Term Debt Issued | - | 190 | 410 | 623.2 | 824.12 | 260 | Upgrade
|
Long-Term Debt Issued | - | 9,994 | 9,995 | 10,270 | 10,251 | 14,971 | Upgrade
|
Total Debt Issued | 9,865 | 10,184 | 10,405 | 10,893 | 11,075 | 15,231 | Upgrade
|
Short-Term Debt Repaid | - | -404.1 | -841.27 | -1,178 | -440 | -622.6 | Upgrade
|
Long-Term Debt Repaid | - | -9,947 | -9,904 | -13,493 | -9,754 | -11,689 | Upgrade
|
Total Debt Repaid | -9,702 | -10,351 | -10,746 | -14,671 | -10,194 | -12,312 | Upgrade
|
Net Debt Issued (Repaid) | 162.86 | -167.48 | -340.33 | -3,778 | 881.37 | 2,920 | Upgrade
|
Issuance of Common Stock | 3 | 3 | 10 | 5.94 | - | 1,360 | Upgrade
|
Common Dividends Paid | -439.16 | -469.07 | -498.58 | -741.6 | -746.79 | -656.84 | Upgrade
|
Other Financing Activities | 1,238 | 1,096 | 124.77 | 35.05 | 180 | -189.5 | Upgrade
|
Financing Cash Flow | 965.09 | 462.74 | -704.14 | -4,479 | 314.58 | 3,433 | Upgrade
|
Foreign Exchange Rate Adjustments | 11.88 | 11.83 | 12.07 | 8.44 | -3.13 | -11.14 | Upgrade
|
Net Cash Flow | 988.14 | 757.4 | -549.56 | -3,994 | 582.42 | 3,331 | Upgrade
|
Free Cash Flow | 113.67 | 445.35 | 401.23 | 454.81 | 502.75 | -254.68 | Upgrade
|
Free Cash Flow Growth | -83.88% | 11.00% | -11.78% | -9.54% | - | - | Upgrade
|
Free Cash Flow Margin | 1.15% | 4.51% | 3.96% | 4.33% | 4.84% | -2.22% | Upgrade
|
Free Cash Flow Per Share | 0.07 | 0.26 | 0.25 | 0.27 | 0.29 | -0.16 | Upgrade
|
Cash Income Tax Paid | 343.58 | 389.03 | 506.93 | 416.57 | 470.37 | 543.86 | Upgrade
|
Levered Free Cash Flow | 503.65 | 388.45 | 156.09 | 181.33 | -902.49 | 539.24 | Upgrade
|
Unlevered Free Cash Flow | 775.86 | 675.14 | 469.77 | 555.95 | -500.81 | 896.76 | Upgrade
|
Change in Net Working Capital | -187.41 | -163.36 | 131.31 | 80.65 | 1,040 | -886.74 | Upgrade
|
Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.